Educational Website for Colorectal Cancer

Recruiting at 338 trial locations

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: SWOG Cancer Research Network

Disqualifiers: Stage IV cancer, Prior malignancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

1057 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial evaluates an online educational tool called Current Together after Cancer (CTAC) to determine if it can help individuals who have undergone stage II or III colorectal cancer surgery adhere more effectively to their surveillance care plans. Proper surveillance care is crucial for early detection of cancer recurrence, yet many survivors miss it due to lack of information or confidence. The trial uses a website to enhance understanding and encourage communication with a supportive person, such as a family member or friend. Individuals who recently had stage II or III colorectal cancer surgery and have a supportive person in their cancer journey may be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking tool for cancer care.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems to focus on an educational website rather than medication changes.

What prior data suggests that this web-based intervention is safe?

Research has shown that the Current Together after Cancer (CTAC) program is an online educational tool designed to improve follow-up care for colorectal cancer survivors. As the program is in a phase III study, it has already passed earlier stages focused on safety. These earlier trials ensured that the program is safe and generally well-tolerated.

Being an online platform, the CTAC program does not cause physical side effects like those from drugs or medical procedures. It aims to educate and empower patients with information, which is typically considered safe. Participants use the website to learn more about their care and how to manage it. So far, other studies have not reported negative effects from using this type of educational tool.

The goal is to enhance knowledge and confidence in managing health, suggesting a low risk for negative outcomes. This makes the CTAC program a safe option for those seeking to better understand their post-cancer care. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the Current Together after Cancer (CTAC) intervention because it offers a fresh approach to supporting colorectal cancer patients and their supporters. Unlike current treatments that focus primarily on medical and surgical interventions, CTAC provides a comprehensive online educational platform. This website empowers users with easily accessible information about managing life after cancer, fostering a sense of control and community. By enhancing understanding and support, CTAC aims to improve the overall well-being and quality of life for everyone involved.

What evidence suggests that the CTAC intervention is effective for increasing guideline-concordant surveillance care in colorectal cancer patients?

Studies have shown that up to 60% of colorectal cancer survivors do not receive the recommended follow-up care after surgery. This gap may result from a lack of understanding about the importance of follow-up or uncertainty about managing their care. In this trial, participants in Group 1 will access the Current Together after Cancer (CTAC) program, an online tool designed to address these issues. The program aims to improve patients' knowledge and confidence in managing their follow-up care. Early results suggest that increased understanding and confidence can lead to more patients receiving appropriate follow-up care. This could help detect any cancer recurrence earlier, when it is easier to treat. ^{1 2 3 4 6}

Who Is on the Research Team?

Christine M Veenstra

Principal Investigator

SWOG Cancer Research Network

Are You a Good Fit for This Trial?

This trial is for adults over 18 who've had stage II or III colorectal cancer surgically removed and are within 90-180 days post-surgery. They should be in fair health (Zubrod status of 0-2) and have a supportive adult willing to engage with an educational website, though the supporter's participation isn't mandatory.

Inclusion Criteria

I don't have another cancer that could affect this treatment's results.

I have a close person who supports me through my treatment.

I have someone who supports me in my colorectal cancer journey and might view a website with me.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive access to the CTAC intervention or control website and may review the content as frequently as they like

16 months

Follow-up

Participants are monitored for knowledge, self-efficacy, and satisfaction with supporter engagement at 3 and 16 months

16 months

What Are the Treatments Tested in This Trial?

Interventions

• Current Together after Cancer (CTAC)

Trial Overview The study tests if an online education platform called Current Together after Cancer (CTAC) can improve follow-up care for colorectal cancer survivors by increasing their knowledge, self-efficacy, and communication with supporters.

How Is the Trial Designed?

Group I: Group 1 (CTAC) Experimental Treatment 3 Interventions

Patients and supporter participants receive access to the CTAC intervention website and may review the content as frequently as they like for up to 16 months on study.

Group II: Group 2 (Control) Active Control 3 Interventions

Patients and supporter participants receive access to a general health education website and may review the content as frequently as they like for up to 16 months on study.

Who Is Running the Clinical Trial?

SWOG Cancer Research Network

Lead Sponsor

Trials

403

Recruited

267,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT07018869

Study Details | NCT07018869 | Evaluating Whether an ... This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with ...

2. cancer.gov cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-03080

Evaluating Whether an Educational Website called Current ... This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with ...

3. centerwatch.com centerwatch.com/clinical-trials/listings/NCT07018869/evaluating-whether-an-educational-website-called-current-together-after-cancer-ctac-improves-follow-up-care-for-colorectal-cancer-survivors

Evaluating Whether an Educational Website Called ... This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of ...

4. clinicaltrials.gov clinicaltrials.gov/study/NCT06995924?lastUpdPost=2020-01-10_

Improving Uptake of Surveillance in Colorectal Cancer ... This pilot clinical trial looks at whether patient navigation services, an interactive web education intervention, called Current Together After Cancer ...

5. swog.org swog.org/clinical-trials/search

Clinical Trials A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline- ...

6. asco.org asco.org/abstracts-presentations/ABSTRACT123196

Updated patient reported outcomes and survivorship care ... Overall, 63% reported chronic changes in bowel patterns, 38% chronic diarrhea, 9% bowel obstruction, 18% hernia development, 8% radiation colitis, and 2% ...